Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've got shares that I went long with...I agree the MRI info and partnership details will be a huge factor in where SYN ends up on a valuation. Good partnership details based on good MRI results and that pushes the need for a capital raise back to the corner of the closet...time will tell...really like the science there...oh and it's a Kirk company too!
Kei...did you see this on SYN...
Synthetic Biologics Wants An Antibiotic Monopoly $SYN http://www.seekingalpha.com/article/3285005
Crossed over 3 in AH trading...
SYN...here's the article out
Synthetic Biologics Wants An Antibiotic Monopoly $SYN
http://www.seekingalpha.com/article/3285005
It does make me feel warm and fuzzy knowing that I've had this gem for over a year. The cards are lining up and we are on the verge of taking the next big step as a company. I believe our current underestimated market cap will get corrected once this deal is announced and the potential for a cash raise fades to the background. The details of the partnership are gonna be the key to where we end up in the valuation though... AIMO
Glad to be here waiting!
New article out on Seeking Alpha focusing on C. Diff. Good read...
Synthetic Biologics Wants An Antibiotic Monopoly $SYN
http://www.seekingalpha.com/article/3285005
Itsthebox1.... These designations are a possibility. However, the PII will have to be completed before a PIII could be started. But if the design of the PII is robust and there is a significant improvement over current SOC any of these drug candidates could fit the bill for an accelerated designation. Triple negative breast cancer I believe could possibly meet the criteria for breakthrough therapy designation due to unmet medical need and it's more aggressive recurrence. Below is a good link that explains the criteria for the different accelerated approval programs.
http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm341027.htm
Im long too. This is my only hold back of stacking my hand deeper. Not trying to take away from the technology at all. I will try to send an email in the next day or so asking about any potential new patent filings. It may be that once more info is derived is PII that they have more to file. I will post reply once I get it.
Well I'd like to see more patents on the IP. I think it is a very unique platform but lack of patents does bother me a little. I would like to hear that more are going to be filed in the near future. This will be crucial for big Pharma to get serious about a buyout in the future.
Do you agree?
Is this data expected near term?
Clinical trial has data collection in October....
https://clinicaltrials.gov/ct2/show/NCT02013050?term=Soligenix&rank=3
Thanks for your input in advance!
Rk...what's your take on the IP for the company?
Thanks Dew!
Was it a general discussion or was TPIV mentioned?
Here's a good read on Herceptin, (it's from 2012). I like this article because it touches on some numbers. Mainly being the unmet medical need.
With over 1.4 million new diagnoses of breast cancer a year, Herceptin at its peak produced almost 6 billion in revenue. At an average of $60k for a 1 yr treatment that equates to around 100k scripts.(obviously I'm ball parking). However, those receiving Herceptin only accounts for about 7% of newly diagnosed breast cancer patients. This is a huge unmet medical need.
I'll be curious to see the cost once we get to that point. There's still a lot that's unknown and will be left to find out after PII is completed.
http://www.medicalnewstoday.com/articles/250912.php
IMO, TPIV is positioned to open up the treatment options for many in this unmet need by the efforts of the Her2 and triple negative indications. Anyway thought I'd share my thoughts....
I am almost positive that low cost was stated on the conference call with Glynn Wilson...
It's not to long if you want to listen again. I'm busy at the moment or I would...
http://services.choruscall.com/links/tpiv150603.html
Sorry catching up here...is "the Apex Study" for VTE due for top line results here shortly. I see on clinical trials that's what it states but it has been a while since it was updated on the site.
TIA
https://clinicaltrials.gov/ct2/show/NCT01583218
With the strength that is being shown I believe it's only a matter of time. And to is right anything under $1.50 seems to get bought up quickly. Nice slow churn...I like the way it's moving...
What I like is the current platform is in oncology but the technology has potential to even be crossed over into infectious disease.
From the company website(also the acronym for why we are called TAP)....
TAP Vector Expression Platform Antigen System TAP (Transporters associated with Antigen Processing) is a central component of the immune system responsible for the processing of antigens and their subsequent presentation to the body’s immune system. TAP-based products have unique and broad application as vaccines for the treatment of both cancer and infectious disease.
....and
In the treatment of infectious disease the use of the company’s TAP technology can make vaccines for microbial pathogens significantly more effective. In animal models vaccines (e.g.smallpox) in the presence of TAP vaccines were 100-1000 times more effective or potent. This offers a highly sought after solution to situations where in a pandemic outbreak like bird flu or H1N1 or a bioterrorism threat, vaccines are insufficient to meet demand. It also means that the amount of vaccine required per dose would be significantly reduced and the often harmful side effects of those vaccines would be substantially reduced or eliminated.
Infectious Disease and National Preparedness is another very significant market and ideal therapeutic area for the TPIV vaccine conjugate. Along with novel peptides and the PolyStart expression system the TPIV vaccine platform can address multiple infectious diseases as well as pandemic and biodefense threats. Our current Smallpox vaccine study at Mayo Clinic has already shown significant benefits over the current vaccine stockpile. It is naturally processed and peptide based, making it safer, longer lasting, cheaper and as effective (in animal studies) as the current product stockpile. The last DHHS contract for a smallpox vaccine stockpile was worth up to $2.8 Billion.
Green is good!
Anybody have LII?
Good luck with that...
Very good news indeed!
Thanks for your take youlie. I'm in it for the long haul anyway so it doesn't affect me really. I'm just curious to see who and the details!
Thanks for those! Looks like a breakout confirmation today on the MACD.
I am wondering if partnership news may still be announced before the end of June...of course that's purely speculation.
Yep my portfolio is up 12% just today.
Big buys coming in right now!!!!!
Rkmatters....I think your view is spot on. Hopefully I can contribute to breaking down the info on data and trial design. I am fairly knowledgeable about clinic outcomes and trial designs as my background is Pharma/biotech sales...
What an excellent well thought out post! Thanks for paying your thoughts'
I have a question for the board to make sure I haven't overlooked any info. Have there been any details to the PII trial design and duration? If not has it been mentioned when this information will likely be released?
TIA
Post #88427 on Sheff's Board
21money21...here it is...
http://theconferenceforum.org/conferences/immuno-oncology-360/overview/
She's presenting. I believe I saw it posted on Sheff's. I'll find it and post it.
TOB...Good to see you here! Thanks for your input...
Just downloaded it! Thanks!
I second that to a sticky!
Wow...that escalated quickly :)
So he had to exercise part of the series C-1(how much?) and purchase an additional 5,000,000 shares?
http://ih.advfn.com/p.php?pid=nmona&article=67346807&symbol=TPIV
....Item 4. Purpose of Transaction.
On June 16, 2015, Eastern Capital Limited gave notice to the Issuer to exercise part of the Issuer’s Series C-1 Warrant at an exercise price of $0.50 per share and to acquire an additional 5,000,000 shares of Common Stock.
....
Thanks for input
Rk.... Just wanted to say thanks real quick for your posts with links to all of these various articles. They were the reason I started doing my DD and ultimately brought me into investing here. I have a pretty small stake in comparison to most here but will be looking to add to my position as things progress
Thanks again...
Stay green!
Mathew633... I see the delay for the MRI scans for Trimesta being pushed out another 30 days. My question is what about partnership details being announced? Are partnership details being released contingent on the MRI scans?
I know I'm ready to see the details!!!!!
You are spot on!
I used the dip to get in. :)
Kicking myself for not getting in at
.30's.